Get complete Patent Opposition Report for Teva Pharmaceuticals

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore patent oppositions filed by Teva Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP2269603Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTISFeb 18, 2016

Explore Teva Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3497104Oct 6, 2021Solid State Forms Of Lumateperone Ditosylate Salt1
EP3344607Nov 6, 2019Solid State Forms Of Selexipag2
EP3045182Mar 7, 2018Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using Same2
EP2688877Mar 8, 2017Solid State Forms Of Cabazitaxel And Processes For Preparation Thereof1